SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical regions of the spine. Its orthobiologics products include demineralized bone matrices, collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to enhance bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. The company offers orthobiologics products in various forms, such as putties, pastes, strips, and resorbable mesh. Its spinal implant portfolio comprises products for spinal decompression, alignment, and stabilization that are used to facilitate fusion in minimally invasive, complex, deformity, and degenerative procedures. The company was incorporated in 2015 and is headquartered in Carlsbad, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone760-727-8399
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$131.81 million
Profitability
Miscellaneous
Employees327
OptionableOptionable
SeaSpine (NASDAQ:SPNE) Frequently Asked Questions
What is SeaSpine's stock symbol?
SeaSpine trades on the NASDAQ under the ticker symbol "SPNE."
How were SeaSpine's earnings last quarter?
SeaSpine Holdings Corp (NASDAQ:SPNE) issued its earnings results on Tuesday, November, 6th. The medical equipment provider reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.53) by $0.12. The medical equipment provider had revenue of $35.83 million for the quarter, compared to analysts' expectations of $35.56 million. SeaSpine had a negative net margin of 22.60% and a negative return on equity of 30.81%. View SeaSpine's Earnings History.
When is SeaSpine's next earnings date?
What guidance has SeaSpine issued on next quarter's earnings?
SeaSpine issued an update on its FY 2018 earnings guidance on Tuesday, November, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $141-142 million, compared to the consensus revenue estimate of $141.16 million.
What price target have analysts set for SPNE?
6 Wall Street analysts have issued 1 year price targets for SeaSpine's shares. Their forecasts range from $17.00 to $23.00. On average, they anticipate SeaSpine's share price to reach $20.50 in the next year. This suggests a possible upside of 31.6% from the stock's current price. View Analyst Price Targets for SeaSpine.
What is the consensus analysts' recommendation for SeaSpine?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SeaSpine in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SeaSpine.
What are Wall Street analysts saying about SeaSpine stock?
Here are some recent quotes from research analysts about SeaSpine stock:
- 1. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating on SeaSpine and 12-month PT of $22. SPNE is a relatively small player (1% market share) in the spine market; however we think that its new product launches and an underappreciated, sizable orthobiologics business should help SPNE differentiate it from other spine companies of similar size. Given the size of the company and the inconsistent results post-spin, we think many investors have not been following the recent progress at the company. We believe SPNE will have to continue to execute and deliver on management’s expectation of exiting the year at high single digit or low double-digit growth to drive appreciation in the stock." (1/7/2019)
- 2. According to Zacks Investment Research, "SeaSpine Holdings Corporation is a medical technology company which focused on the design, development and commercialization of surgical solutions for the treatment of spinal disorders. The company also offers orthobiologics and spinal fusion hardware solutions. SeaSpine Holdings Corporation is headquartered in Vista, California. " (11/16/2018)
Has SeaSpine been receiving favorable news coverage?
Media stories about SPNE stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. SeaSpine earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave press coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days.
Who are some of SeaSpine's key competitors?
Some companies that are related to SeaSpine include Cryolife (CRY), Cardiovascular Systems (CSII), Orthofix Medical (OFIX), Intersect ENT (XENT), AngioDynamics (ANGO), Cerus (CERS), OraSure Technologies (OSUR), SurModics (SRDX), SI-Bone (SIBN), Anika Therapeutics (ANIK), Inovio Pharmaceuticals (INO), Antares Pharma (ATRS), LeMaitre Vascular (LMAT), Orthopediatrics (KIDS) and Axonics Modulation Technologies (AXNX).
Who are SeaSpine's key executives?
SeaSpine's management team includes the folowing people:
- Mr. Keith C. Valentine, Pres, CEO & Director (Age 51)
- Mr. John J. Bostjancic, Sr. VP, CFO & Treasurer (Age 48)
- Mr. Patrick L. Keran, VP, Gen. Counsel & Corp. Sec. (Age 47)
- Carrie Mendivil, Head of Investor Relations
- Mr. John J. Winge, VP of Sales (Age 52)
How do I buy shares of SeaSpine?
Shares of SPNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SeaSpine's stock price today?
One share of SPNE stock can currently be purchased for approximately $15.58.
How big of a company is SeaSpine?
SeaSpine has a market capitalization of $288.74 million and generates $131.81 million in revenue each year. The medical equipment provider earns $-32,110,000.00 in net income (profit) each year or ($2.58) on an earnings per share basis. SeaSpine employs 327 workers across the globe.
What is SeaSpine's official website?
How can I contact SeaSpine?
SeaSpine's mailing address is 5770 ARMADA DRIVE, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-727-8399 or via email at [email protected]
MarketBeat Community Rating for SeaSpine (NASDAQ SPNE)
MarketBeat's community ratings are surveys of what our community members think about SeaSpine and other stocks. Vote "Outperform" if you believe SPNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
